Nuvation Bio Inc. | Small-cap | Healthcare
$3.14
-6.27%
| Nuvation Bio Stock Comparison:
Nuvation Bio vs VertexNuvation Bio vs AlnylamNuvation Bio vs AdaptiveNuvation Bio vs Dyne TherapeuticsNuvation Bio vs Harmony BiosciencesNuvation Bio vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 4.8M
Gross Profit 2.3M 46.70%
Operating Income -63.6M -1,315.73%
Net Income -59.0M -1,220.92%
EPS (Diluted) $-0.17

Balance Sheet Metrics

Total Assets 492.5M
Total Liabilities 73.0M
Shareholders Equity 419.5M
Debt to Equity 0.17

Cash Flow Metrics

Operating Cash Flow -32.1M
Free Cash Flow -42.7M

Revenue & Profitability Trend

Nuvation Bio Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i7.9M0000
Cost of Goods Sold i7.1M----
Gross Profit i795.0K----
Gross Margin % i10.1%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i524.2M71.3M87.8M69.0M32.6M
Selling, General & Administrative i69.2M28.5M31.9M24.3M10.9M
Other Operating Expenses i-----
Total Operating Expenses i593.4M99.8M119.7M93.3M43.6M
Operating Income i-592.6M-99.8M-119.7M-93.3M-43.6M
Operating Margin % i-7,527.3%0.0%0.0%0.0%0.0%
Non-Operating Items
Interest Income i27.1M24.6M7.4M3.0M1.9M
Interest Expense i341.0K----
Other Non-Operating Income-2.0M-591.0K8.1M3.5M-53.0K
Pre-tax Income i-567.9M-75.8M-104.2M-86.8M-41.7M
Income Tax i00000
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-567.9M-75.8M-104.2M-86.8M-41.7M
Net Margin % i-7,213.8%0.0%0.0%0.0%0.0%
Key Metrics
EBITDA i-566.0M-100.0M-128.5M-97.3M-43.7M
EPS (Basic) i$-2.11$-0.35$-0.48$-0.44$-0.19
EPS (Diluted) i$-2.11$-0.35$-0.48$-0.44$-0.19
Basic Shares Outstanding i268772000218880000216721000197887000217650055
Diluted Shares Outstanding i268772000218880000216721000197887000217650055

Income Statement Trend

Nuvation Bio Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i35.7M42.6M101.1M132.4M29.8M
Short-term Investments i467.0M568.6M559.9M633.0M186.0M
Accounts Receivable i12.7M----
Inventory i-----
Other Current Assets7.3M1.5M3.8M3.6M914.0K
Total Current Assets i526.3M616.4M667.3M772.1M220.7M
Non-Current Assets
Property, Plant & Equipment i2.4M3.6M3.8M2.9M0
Goodwill i4.6M----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets6.6M587.0K---
Total Non-Current Assets i14.4M5.0M4.8M4.1M1.1M
Total Assets i540.6M621.5M672.1M776.2M221.8M
Liabilities
Current Liabilities
Accounts Payable i6.3M2.2M2.1M3.9M2.2M
Short-term Debt i7.9M2.0M1.2M863.0K-
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i58.2M14.0M13.2M16.9M6.6M
Non-Current Liabilities
Long-term Debt i969.0K2.0M3.1M2.2M0
Deferred Tax Liabilities i-----
Other Non-Current Liabilities-----
Total Non-Current Liabilities i18.6M2.4M3.9M13.2M157.0K
Total Liabilities i76.8M16.4M17.1M30.2M6.7M
Equity
Common Stock i1.4B947.7M927.6M910.0M289.5M
Retained Earnings i-910.7M-342.8M-267.0M-162.8M-76.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i463.8M605.1M655.1M746.0M215.1M
Key Metrics
Total Debt i8.9M4.0M4.3M3.1M0
Working Capital i468.0M602.5M654.2M755.1M214.1M

Balance Sheet Composition

Nuvation Bio Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-567.9M-75.8M-104.2M-86.8M-41.7M
Depreciation & Amortization i683.0K222.0K199.0K184.0K103.0K
Stock-Based Compensation i32.3M19.5M16.3M9.3M2.2M
Working Capital Changes i-16.3M-1.7M-949.0K-243.0K-84.0K
Operating Cash Flow i-126.4M-57.9M-88.4M-73.7M-39.4M
Investing Activities
Capital Expenditures i-162.0K-55.0K-357.0K-282.0K-145.0K
Acquisitions i12.4M----
Investment Purchases i-339.6M-703.4M-520.3M-609.3M-143.3M
Investment Sales i450.1M712.3M584.1M154.9M73.1M
Investing Cash Flow i122.7M8.9M63.5M-454.7M-70.3M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i-----
Debt Repayment i-17.2M----
Financing Cash Flow i-21.7M--624.8M133.1M
Free Cash Flow i-130.6M-68.1M-96.5M-68.5M-36.7M
Net Change in Cash i-25.4M-48.9M-24.9M96.4M23.4M

Cash Flow Trend

Nuvation Bio Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -1.49
Forward P/E -4.98
Price to Book 2.88
Price to Sales 74.87
PEG Ratio 0.02

Profitability Ratios

Profit Margin 10.10%
Operating Margin -1,315.72%
Return on Equity -44.84%
Return on Assets 20.17%

Financial Health

Current Ratio 9.39
Debt to Equity 15.49
Beta 1.37

Per Share Data

EPS (TTM) $-0.38
Book Value per Share $1.09
Revenue per Share $0.04

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
nuvb1.1B-1.492.88-44.84%10.10%15.49
Vertex 101.2B28.085.8922.77%31.86%8.89
Alnylam 61.1B-213.71244.95-257.83%-12.96%1,093.31
Adaptive 1.9B-11.6810.68-57.60%-59.07%121.39
Dyne Therapeutics 1.9B-3.902.63-61.32%0.00%21.19
Harmony Biosciences 1.9B10.452.4127.58%23.42%22.43

Financial data is updated regularly. All figures are in the company's reporting currency.